Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
Recruiting · Not applicable · NCT07222410
Conditions: COPD
At a glance
- Research payments reported, 2025
- $56,134
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- Fisher and Paykel Healthcare
- Tested
- Closed loop oxygen control (device), Manual titration (device)
- Dates
- Started 2026-01-07; completion 2027-11
- Results posted
- Not yet
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Fisher & Paykel Healthcare Limited reported $56,134 in research payments for this study in 2025 (2 payments).
Products named: Fisher & PAykel Healthcare
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.